{"transactions":[{"id":1001949,"issuer":{"id":7001,"kind":"organization","name":"Annovis Bio, Inc."},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option","published_at":"2025-11-12T14:17:18.000Z","date":"2025-09-10","kind":"exercise","planned":false,"acquired":false,"shares":7142,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.14,"exercise_date":"2016-09-18","expiration_date":"2025-09-18","underlying":"Common Stock","underlying_shares":7142},"source":{"system":"sec-edgar","filing":"0001104659-25-109904","document":"tm2527472-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925109904/tm2527472-1_4seq1.xml","form_type":"4"}},{"id":1001948,"issuer":{"id":7001,"kind":"organization","name":"Annovis Bio, Inc."},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T14:17:18.000Z","date":"2025-09-10","kind":"exercise","planned":false,"acquired":true,"shares":7142,"price":0.14,"value":999.88,"ownership":{"direct":true},"balance_after":13709,"source":{"system":"sec-edgar","filing":"0001104659-25-109904","document":"tm2527472-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925109904/tm2527472-1_4seq1.xml","form_type":"4"}},{"id":1459839,"issuer":{"id":7001,"kind":"organization","name":"Annovis Bio, Inc."},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-03T21:15:43.000Z","date":"2023-11-17","kind":"grant","planned":false,"acquired":true,"shares":26200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest immediately upon grant date."}],"balance_after":26200,"derivative":{"exercise_price":6.07,"expiration_date":"2033-11-17","underlying":"Common Stock","underlying_shares":26200},"source":{"system":"sec-edgar","filing":"0001104659-24-077831","document":"tm2417696-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924077831/tm2417696-1_4seq1.xml","form_type":"4"}},{"id":1731159,"issuer":{"id":7001,"kind":"organization","name":"Annovis Bio, Inc."},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-22T21:14:47.000Z","date":"2023-11-20","kind":"other","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amendment is being filed solely to reverse the previously reported purchase on the original form 4 filed on November 21, 2023 (the \"Original Form 4\"). Such purchase was rescinded by the registrant and the reporting person on November 22, 2023."}],"balance_after":6567,"source":{"system":"sec-edgar","filing":"0001104659-23-120749","document":"tm2331305-7_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465923120749/tm2331305-7_4aseq1.xml","form_type":"4/A","original_submission_date":"2023-11-21"}},{"id":1732544,"issuer":{"id":7001,"kind":"organization","name":"Annovis Bio, Inc."},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T19:27:58.000Z","date":"2023-11-20","kind":"grant","planned":false,"acquired":true,"shares":1000,"price":6.07,"value":6070.0,"ownership":{"direct":true},"balance_after":7567,"source":{"system":"sec-edgar","filing":"0001104659-23-120299","document":"tm2331305-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465923120299/tm2331305-1_4seq1.xml","form_type":"4"}},{"id":1921742,"issuer":{"id":7001,"kind":"organization","name":"Annovis Bio, Inc."},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-12T01:11:11.000Z","date":"2023-04-07","kind":"grant","planned":false,"acquired":true,"shares":500,"price":12.61,"value":6305.0,"ownership":{"direct":true},"balance_after":6567,"source":{"system":"sec-edgar","filing":"0001104659-23-044208","document":"tm2312464-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465923044208/tm2312464-5_4seq1.xml","form_type":"4"}},{"id":2049645,"issuer":{"id":7001,"kind":"organization","name":"Annovis Bio, Inc."},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-20T22:37:35.000Z","date":"2023-01-18","kind":"grant","acquired":true,"shares":5967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in eight consecutive equal quarterly installments each on the 18th day of April, July, October and January of each year, commencing April 18, 2023, and continuing through January 18, 2025."}],"balance_after":5967,"derivative":{"exercise_price":13.17,"expiration_date":"2033-01-18","underlying":"Common Stock","underlying_shares":5967},"source":{"system":"sec-edgar","filing":"0001104659-23-005475","document":"tm234043-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465923005475/tm234043-1_4seq1.xml","form_type":"4"}},{"id":2443813,"issuer":{"id":7001,"kind":"organization","name":"Annovis Bio, Inc."},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T00:40:57.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in eight consecutive quarterly installments of 1,000 shares each on the 3rd day of April, July, October and January of each year, commencing April 3, 2022, and continuing through January 3, 2024."}],"balance_after":8000,"derivative":{"exercise_price":19.78,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001104659-22-001637","document":"tm221949-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465922001637/tm221949-1_4seq1.xml","form_type":"4"}},{"id":2543371,"issuer":{"id":7001,"kind":"organization","name":"Annovis Bio, Inc."},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-13T20:03:10.000Z","date":"2021-10-11","kind":"purchase","acquired":true,"shares":181,"price":27.66,"value":5006.46,"ownership":{"direct":true},"balance_after":6067,"source":{"system":"sec-edgar","filing":"0001415889-21-004864","document":"form4-10132021_011056.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477845/000141588921004864/form4-10132021_011056.xml","form_type":"4"}},{"id":2637008,"issuer":{"id":7001,"kind":"organization","name":"Annovis Bio, Inc."},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-09T22:25:56.000Z","date":"2021-07-07","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in eight substantially equal quarterly installments beginning October 7, 2021, provided that the reporting person continues to serve as a director of the issuer on the applicable vesting date."}],"balance_after":4000,"derivative":{"exercise_price":102.85,"expiration_date":"2031-07-07","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001104659-21-090741","document":"tm2121908-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465921090741/tm2121908-1_4seq1.xml","form_type":"4"}},{"id":2640159,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-07-07T17:44:54.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":3969,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Stock issued under the Amended and Restated 2014 Stock Incentive Plan in partial payment of quarterly non-employee director fees."}],"balance_after":16519,"source":{"system":"sec-edgar","filing":"0001437749-21-016596","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774921016596/rdgdoc.xml","form_type":"4"}},{"id":2907679,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true}}],"security":"Stock Option","published_at":"2021-01-14T16:35:14.000Z","date":"2021-01-13","kind":"grant","acquired":true,"shares":2500,"price":0.001,"value":2.5,"ownership":{"direct":true},"balance_after":2500,"derivative":{"exercise_price":2.28,"exercise_date":"2022-01-13","expiration_date":"2031-01-13","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001437749-21-000725","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774921000725/rdgdoc.xml","form_type":"4"}},{"id":2907678,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-01-14T16:35:14.000Z","date":"2021-01-13","kind":"grant","acquired":true,"shares":2500,"price":0.001,"value":2.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant."}],"balance_after":12550,"source":{"system":"sec-edgar","filing":"0001437749-21-000725","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774921000725/rdgdoc.xml","form_type":"4"}},{"id":3088738,"issuer":{"id":7001,"kind":"organization","name":"Annovis Bio, Inc."},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-06T20:32:57.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20000,"derivative":{"exercise_price":4.39,"exercise_date":"2020-07-01","expiration_date":"2030-07-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-20-081248","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465920081248/a4.xml","form_type":"4"}},{"id":3285539,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true}}],"security":"Stock Option","published_at":"2020-02-07T16:09:16.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":2500,"price":0.001,"value":2.5,"ownership":{"direct":true},"balance_after":7500,"derivative":{"exercise_price":1.06,"exercise_date":"2021-02-06","expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001437749-20-002027","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774920002027/rdgdoc.xml","form_type":"4"}},{"id":3285538,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-02-07T16:09:16.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":2500,"price":0.001,"value":2.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the on-year anniversary of the date of grant."}],"balance_after":10050,"source":{"system":"sec-edgar","filing":"0001437749-20-002027","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774920002027/rdgdoc.xml","form_type":"4"}},{"id":3288602,"issuer":{"id":7001,"kind":"organization","name":"Annovis Bio, Inc."},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Note","published_at":"2020-02-05T11:04:26.000Z","date":"2020-01-31","kind":"exercise","acquired":false,"shares":1117,"price":4.8,"value":5361.6,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price)."},{"field":"shares","element":"transactionShares","label":"F3","text":"The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price)."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1117},"source":{"system":"sec-edgar","filing":"0001104659-20-010940","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465920010940/a4.xml","form_type":"4"}},{"id":3288601,"issuer":{"id":7001,"kind":"organization","name":"Annovis Bio, Inc."},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2020-02-05T11:04:26.000Z","date":"2020-01-31","kind":"exercise","acquired":false,"shares":5556,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3969},"source":{"system":"sec-edgar","filing":"0001104659-20-010940","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465920010940/a4.xml","form_type":"4"}},{"id":3288600,"issuer":{"id":7001,"kind":"organization","name":"Annovis Bio, Inc."},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-05T11:04:26.000Z","date":"2020-01-31","kind":"exercise","acquired":true,"shares":1117,"price":4.8,"value":5361.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price)."}],"balance_after":5886,"source":{"system":"sec-edgar","filing":"0001104659-20-010940","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465920010940/a4.xml","form_type":"4"}},{"id":3288599,"issuer":{"id":7001,"kind":"organization","name":"Annovis Bio, Inc."},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-05T11:04:26.000Z","date":"2020-01-31","kind":"exercise","acquired":true,"shares":3969,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143."}],"balance_after":4769,"source":{"system":"sec-edgar","filing":"0001104659-20-010940","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465920010940/a4.xml","form_type":"4"}},{"id":3288598,"issuer":{"id":7001,"kind":"organization","name":"Annovis Bio, Inc."},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-05T11:04:26.000Z","date":"2020-01-31","kind":"purchase","acquired":true,"shares":800,"price":6,"value":4800.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person acquired these shares in the initial public offering (\"IPO\") of Annovis Bio, Inc. (\"Annovis\")."}],"balance_after":800,"source":{"system":"sec-edgar","filing":"0001104659-20-010940","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465920010940/a4.xml","form_type":"4"}},{"id":3526924,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-05-15T16:06:15.000Z","date":"2019-05-13","kind":"purchase","acquired":true,"shares":2550,"price":1.904,"value":4855.2,"ownership":{"direct":true},"balance_after":7550,"source":{"system":"sec-edgar","filing":"0001437749-19-010057","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774919010057/rdgdoc.xml","form_type":"4"}},{"id":3664331,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true}}],"security":"Stock Option","published_at":"2019-02-12T16:10:55.000Z","date":"2019-02-07","kind":"grant","acquired":true,"shares":50000,"price":0.001,"value":50.0,"ownership":{"direct":true},"balance_after":100000,"derivative":{"exercise_price":0.25,"exercise_date":"2020-02-07","expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001437749-19-002329","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774919002329/rdgdoc.xml","form_type":"4"}},{"id":3664330,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-02-12T16:10:55.000Z","date":"2019-02-07","kind":"grant","acquired":true,"shares":50000,"price":0.001,"value":50.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001437749-19-002329","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774919002329/rdgdoc.xml","form_type":"4"}},{"id":3993792,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true}}],"security":"Stock Option","published_at":"2018-03-16T10:43:21.000Z","date":"2018-03-15","kind":"grant","acquired":true,"shares":50000,"price":0.001,"value":50.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":0.75,"exercise_date":"2019-03-15","expiration_date":"2028-03-15","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001437749-18-004830","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774918004830/rdgdoc.xml","form_type":"4"}},{"id":3993791,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":73316,"kind":"person","name":"Bruck Claudine","position":1,"cik":"0001733680","reported_name":"Bruck Claudine","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-03-16T10:43:21.000Z","date":"2018-03-15","kind":"grant","acquired":true,"shares":50000,"price":0.001,"value":50.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001437749-18-004830","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774918004830/rdgdoc.xml","form_type":"4"}}]}